143 related articles for article (PubMed ID: 33183197)
1. Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo.
Wang M; Du Q; Zuo L; Xue P; Lan C; Sun Z
Curr Drug Metab; 2020; 21(13):996-1008. PubMed ID: 33183197
[TBL] [Abstract][Full Text] [Related]
2. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
Teo YL; Ho HK; Chan A
Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
[TBL] [Abstract][Full Text] [Related]
4. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
[TBL] [Abstract][Full Text] [Related]
6. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
Wang X; Zhang X; Liu F; Wang M; Qin S
Pharm Biol; 2017 Dec; 55(1):1863-1867. PubMed ID: 28614959
[TBL] [Abstract][Full Text] [Related]
7. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
[TBL] [Abstract][Full Text] [Related]
8. Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs.
Williamson B; Pilla Reddy V
Biopharm Drug Dispos; 2021 Apr; 42(4):128-136. PubMed ID: 33759216
[TBL] [Abstract][Full Text] [Related]
9. Comment on: "CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients".
Oude Munnink TH; Klein SK; Touw DJ
Clin Pharmacokinet; 2024 Jun; 63(6):917-918. PubMed ID: 38734861
[No Abstract] [Full Text] [Related]
10. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
12. Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Cotreau MM; Siebers NM; Miller J; Strahs AL; Slichenmyer W
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):137-42. PubMed ID: 27128217
[TBL] [Abstract][Full Text] [Related]
13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of food-drug interactions with small-molecule kinase inhibitors.
Veerman GDM; Hussaarts KGAM; Jansman FGA; Koolen SWL; van Leeuwen RWF; Mathijssen RHJ
Lancet Oncol; 2020 May; 21(5):e265-e279. PubMed ID: 32359502
[TBL] [Abstract][Full Text] [Related]
15. Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.
Bahce I; Yaqub M; Smit EF; Lammertsma AA; van Dongen GA; Hendrikse NH
Lung Cancer; 2017 May; 107():1-13. PubMed ID: 27319335
[TBL] [Abstract][Full Text] [Related]
16. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic studies of nanoparticles as a delivery system for conventional drugs and herb-derived compounds for cancer therapy: a systematic review.
Abdifetah O; Na-Bangchang K
Int J Nanomedicine; 2019; 14():5659-5677. PubMed ID: 31632004
[TBL] [Abstract][Full Text] [Related]
18. [Management of targeted therapies in hemodialysis patients].
Janus N; Launay-Vacher V; Deray G; Islam MS; Thyss A; Thariat J
Bull Cancer; 2012 Mar; 99(3):381-8. PubMed ID: 22133789
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic issues on cancer pharmacotherapy].
Tanigawara Y
Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
[TBL] [Abstract][Full Text] [Related]
20. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
